319 related articles for article (PubMed ID: 32756606)
1. Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain.
Bernardi A; Huang Y; Harris B; Xiong Y; Nandi S; McDonald KA; Faller R
PLoS One; 2020; 15(8):e0237295. PubMed ID: 32756606
[TBL] [Abstract][Full Text] [Related]
2. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.
Zhao P; Praissman JL; Grant OC; Cai Y; Xiao T; Rosenbalm KE; Aoki K; Kellman BP; Bridger R; Barouch DH; Brindley MA; Lewis NE; Tiemeyer M; Chen B; Woods RJ; Wells L
Cell Host Microbe; 2020 Oct; 28(4):586-601.e6. PubMed ID: 32841605
[TBL] [Abstract][Full Text] [Related]
3. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
Peters MH; Bastidas O; Kokron DS; Henze CE
PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
6. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
7. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X; Chen Z; Xia Y; Lin W; Li H
J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
[TBL] [Abstract][Full Text] [Related]
9. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
11. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor.
Yang Y; Du Y; Kaltashov IA
Anal Chem; 2020 Aug; 92(16):10930-10934. PubMed ID: 32678978
[TBL] [Abstract][Full Text] [Related]
12. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
13. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.
Dong J; Huang B; Wang B; Titong A; Gallolu Kankanamalage S; Jia Z; Wright M; Parthasarathy P; Liu Y
Sci Rep; 2020 Oct; 10(1):17806. PubMed ID: 33082473
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition.
Grant OC; Montgomery D; Ito K; Woods RJ
Sci Rep; 2020 Sep; 10(1):14991. PubMed ID: 32929138
[TBL] [Abstract][Full Text] [Related]
15. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the adhesive strength between the SARS-CoV-2 S-proteins and human receptor and its effect in therapeutics.
Ponga M
Sci Rep; 2020 Oct; 10(1):17538. PubMed ID: 33067518
[TBL] [Abstract][Full Text] [Related]
17. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
[TBL] [Abstract][Full Text] [Related]
18. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction.
Hanke L; Vidakovics Perez L; Sheward DJ; Das H; Schulte T; Moliner-Morro A; Corcoran M; Achour A; Karlsson Hedestam GB; Hällberg BM; Murrell B; McInerney GM
Nat Commun; 2020 Sep; 11(1):4420. PubMed ID: 32887876
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Clausen TM; Sandoval DR; Spliid CB; Pihl J; Perrett HR; Painter CD; Narayanan A; Majowicz SA; Kwong EM; McVicar RN; Thacker BE; Glass CA; Yang Z; Torres JL; Golden GJ; Bartels PL; Porell RN; Garretson AF; Laubach L; Feldman J; Yin X; Pu Y; Hauser BM; Caradonna TM; Kellman BP; Martino C; Gordts PLSM; Chanda SK; Schmidt AG; Godula K; Leibel SL; Jose J; Corbett KD; Ward AB; Carlin AF; Esko JD
Cell; 2020 Nov; 183(4):1043-1057.e15. PubMed ID: 32970989
[TBL] [Abstract][Full Text] [Related]
20. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
